Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 695 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Liquid Placebo Clear all
Completed Phase 2 Interventional Results available

Citrulline in Severe Sepsis

NCT01474863
View directory record Official record
Conditions
Severe Sepsis, Acute Lung Injury
Interventions
High Dose Citrulline, Placebo, Low Dose Citrulline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 3, 2026, 10:38 PM EDT
Active, not recruiting Phase 2 Interventional

Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders

NCT06503978
View directory record Official record
Conditions
Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
Interventions
MTP-101P, Vancomycin, Miralax, Antacid, Placebo MTP-101P, Placebo Vancomycin
Combination Product
Lead sponsor
Gut-Brain-Axis Therapeutics Inc.
Other
Eligibility
4 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 3, 2026, 10:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First Safety Study in Humans of a Single Dose of CPG 52364

NCT00547014
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo Comparator: Cohort 1 Placebo, 52364 3 mg, Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo, 52364 10 mg, 52364 30 mg, 52364 100 mg, 52364 1 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2009 · Synced Sep 3, 2026, 10:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.

NCT03379168
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Microfragmented Adipose Tissue (Lipogems), Corticosteroid injection, Saline
Device · Drug
Lead sponsor
Dustin L. Richter, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 3, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

NCT04470427
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30,415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
100
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Sep 3, 2026, 10:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Phenytoin for Memory Impairment Secondary to Megestrol

NCT02595723
View directory record Official record
Conditions
Cognitive Impairment
Interventions
Phenytoin 200 mg capsule, Megestrol 800 mg liquid, Phenytoin-matched Placebo capsule, Megestrol-matched liquid Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Sep 3, 2026, 10:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vitamin D Absorbance Study - Clinical Trial of the Absorbance of Nano Liquid D3

NCT04885803
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Softgel Vitamin D3, Nano Liquid Vitamin D3, 25(OH)D Blood Serum Test, Placebo Control
Dietary Supplement · Diagnostic Test · Other
Lead sponsor
Inspired Life Medical, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Le Sueur, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Sep 3, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

Sapropterin as a Treatment for Autistic Disorder

NCT00850070
View directory record Official record
Conditions
Autistic Disorder
Interventions
sapropterin, Placebo
Drug
Lead sponsor
The Children's Health Council
Other
Eligibility
3 Years to 6 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Sep 3, 2026, 10:38 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones

NCT04387617
View directory record Official record
Conditions
Urinary Stone
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Sep 3, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

NCT00221403
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperidone oral solution, Valproate Oral Solution, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 7 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 3, 2026, 10:38 PM EDT
Recruiting Phase 4 Interventional

Multi-Center PAMPA Study

NCT05004727
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 3, 2026, 10:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Behavior and Exercise Versus Drug Treatment in Men With Nocturia (BEDTiMe)

NCT00824200
View directory record Official record
Conditions
Nocturia
Interventions
Behavioral, tamsulosin (alpha-adrenergic antagonist medication), placebo, placebo
Behavioral · Drug
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
40 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
2
States / cities
Birmingham, Alabama • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 3, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients

NCT02640807
View directory record Official record
Conditions
Severe Sepsis With Septic Shock
Interventions
Interleukin-7, Placebo
Drug
Lead sponsor
Revimmune
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 3, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis

NCT00906399
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
BIIB017 (peginterferon beta-1a), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
12
States / cities
Phoenix, Arizona • Ponte Vedra Beach, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Sep 3, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects

NCT02891837
View directory record Official record
Conditions
Acute Lung Injury
Interventions
L-citrulline, Placebo
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
Up to 18 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Loma Linda, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 3, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

NCT03580356
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,078 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 3, 2026, 10:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine

NCT00873912
View directory record Official record
Conditions
Healthy
Interventions
Monovalent influenza virus vaccine, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Sep 3, 2026, 10:38 PM EDT
Recruiting Phase 3 Interventional

Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis

NCT04411225
View directory record Official record
Conditions
Early Psychosis
Interventions
Cannabidiol oral solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
16 Years to 30 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 3, 2026, 10:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

Vaginal Microbiota Transplant

NCT04046900
View directory record Official record
Conditions
Recurrent Bacterial Vaginosis
Interventions
Vaginal microbiome transplant, Oral Metronidazole, Sterile saline
Biological · Drug · Other
Lead sponsor
Douglas Kwon
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 3, 2026, 10:38 PM EDT
Terminated Phase 3 Interventional Results available

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia

NCT01227512
View directory record Official record
Conditions
Hyponatremia, Dilutional Hyponatremia, Inappropriate ADH Syndrome
Interventions
tolvaptan, Fluid Restriction
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
56
States / cities
Birmingham, Alabama • Mobile, Alabama • Azusa, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Sep 3, 2026, 10:38 PM EDT
Completed No phase listed Observational

Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis

NCT02330965
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
Blood Draw, CSF collection by lumbar puncture (Optional)
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Berkeley, California • Los Angeles, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 3, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT02584959
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
C1 esterase inhibitor [human] liquid, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 3, 2026, 10:38 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy

NCT01951716
View directory record Official record
Conditions
Does the Vagus Nerve Mediate the Effects of Xenin-25
Interventions
Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone, Graded Glucose Infusion with GIP plus xenin-25, Meal Tolerance Test with Placebo, Meal Tolerance Test with xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 3, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

NCT01565707
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Solifenacin Succinate Suspension, Placebo, Urotherapy
Drug · Behavioral
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
5 Years to 17 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Shreveport, Louisiana • Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 3, 2026, 10:38 PM EDT